In recent years, with the continuous enhancement of innovation strength, more and more Chinese innovative pharmaceutical companies are on the road
of accelerating "going to sea".
At present, "going to sea" not only opens up a new channel for the development of domestic pharmaceutical companies, but also provides more new choices of "Chinese good medicine" for global patients
.
On December 5, Sinovac and partner PT Etana Biotechnologies Indonesia jointly announced that SINOVAC Sinovac hepatitis A inactivated vaccine Childreflex ® was officially launched
in Indonesia.
It is reported that Children's Liber ® was approved
by the Indonesian Food and Drug Administration in February this year.
In November, Sinovac's inactivated enterovirus 71 (EV71) vaccine was also approved
in Indonesia.
The industry believes that the launch of Childlife will further meet the growing demand
for high-quality vaccine products in Indonesia.
In fact, going overseas has long become an important way for domestic innovative pharmaceutical companies to explore new business growth points, and in recent years, more and more Chinese pharmaceutical companies are entering the international market while also promoting a large number of domestic new drugs overseas
.
For example, in November, Hutchison Pharma announced that its new anti-cancer drug fruquintinib has shown significant clinical benefits
in the study of advanced gastric cancer or gastroesophageal junction adenocarcinoma in combination with paclitaxel.
The "going to sea" of fruquintinib is steadily advancing
.
According to the plan, Hutchison will submit new drug applications
in the United States, Europe and Japan in 2023 based on international multi-center clinical research data.
On September 26, Frontier Biotech mentioned at the performance statement meeting that Ekonin has obtained the marketing registration authorization of drugs in Malaysia and submitted drug registration applications
in 7 countries.
The company said that it will continue to actively promote the commercialization process of Ekonin overseas in close connection with the business plan it has formulated, with a view to realizing the overseas business income
of Ekonin.
Up to now, Ekonin has obtained drug marketing registration authorization in Ecuador, Cambodia and Malaysia, submitted drug registration applications in 7 countries, and launched drug registration in 5 countries
.
In June, Hansen Pharmaceutical's application for the first-line treatment of EGFR mutation advanced or metastatic NSCLC was accepted in the UK (MHRA), which is expected to become the first innovative drug
of similar domestic varieties to be successfully launched overseas.
.
.
.
.
.
.
It is worth mentioning that the continuous "going abroad" of domestic new drugs is still bringing more incremental market space
to pharmaceutical companies.
It is reported that in 2019, BeiGene's self-developed anticancer drug zebratinib was approved by the US FDA
.
In the first half of 2022, the global sales of zebratinib reached 1.
514 billion yuan, a year-on-year increase of 263%.
In general, affected by a series of factors such as favorable policies, capital and talent return, Chinese pharmaceutical companies are enthusiastic about innovation, and the pace of going overseas is also accelerating
.
Data shows that as of the end of April 2022, the number of domestic innovative pharmaceutical companies going overseas has reached 123, including Hengrui, BeiGene, Fosun Pharma, etc
.
Affected by this, the number of domestic drugs approved for trial, clinical, new indications and marketing overseas is also increasing
.
In the future, the industry expects that many overseas emerging markets will become a must-compete place and a new incremental market
for domestic pharmaceutical companies, especially innovative pharmaceutical companies.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
